Richard Fuerstenberg

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to(More)
  • 1